Compare Sanofi SA (SNY) vs Silvercorp Metals Inc. Common Shares (SVM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Silvercorp Metals Inc. Common Shares — how do they compare? Sanofi SA trades at $40.49 (market cap $96.38B), while Silvercorp Metals Inc. Common Shares trades at $9.65 (market cap $2.09B). The key difference: Sanofi SA is far larger — about 46.1× Silvercorp Metals Inc. Common Shares's market cap, and Sanofi SA pays the higher dividend (6.08%). Which is the better fit depends on your goals — on Pluang, investors hold Sanofi SA for 94 Days and Silvercorp Metals Inc. Common Shares for 0 Days on average.
| SNY | SVM | |
|---|---|---|
Market Cap | $96.38B | $2.09B |
Volume | 5,335,342 | 3,359,240 |
Sector | Health | Basic Materials |
52-Week High | $52.34 | $15.71 |
52-Week Low | $39.12 | $6.09 |
Typical Hold Time | 94 Days | 0 Days |
Enterprise Value | $115.67B | $1.82B |
Dividend Yield | 6.08% | 0.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $39.12, down 1.56% on the day, amid a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21, and revenue for 2025 reached $46.72B. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, potentially driving future growth. Analyst consensus is mixed, with 44% buy ratings but a majority hold stance.
The outlook is cautiously optimistic, supported by earnings beats and strategic partnerships, but risks include a projected net income decline in 2026 and competitive pressures. The stock's current valuation metrics, such as a P/E of 22.06, appear reasonable relative to historical performance, though investor sentiment remains tempered by near-term challenges.
Silvercorp Metals (SVM) trades at $10.03, down 2.62% on the day, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q1 2026 but missing in Q4 2025 and Q2 2026. Revenue grew significantly from $299M in 2025 to $495M in 2026, though net income margin compressed. Analyst consensus is 60% buy with no sell ratings. Recent news highlights expansion into Ecuador and Kyrgyzstan to diversify geographic risk and a renewed share repurchase program.
The outlook is cautiously optimistic, driven by production expansion and strong operational cash flow, but tempered by execution risks in new jurisdictions and margin pressure. Key opportunities include global growth initiatives and efficient cost structure, while risks involve geopolitical exposure and volatile metal prices.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Silvercorp Metals Inc. Common Shares
Silvercorp Metals Inc. is a Canadian mining company that operates underground silver-lead-zinc mines and processing plants in China, with additional exploration projects in Ecuador.
Read more on SVM →
